Search clinical trials for: Ga-68 labeled PSMA-11 PET

Total 188 results

Mayo Clinic

No longer available

Expanded Access [Ga-68] PSMA-11 PET Imaging

Prostate Cancer

United States
Thomas Hope
Gateway for Cancer Research; Prostate Cancer Foundation; Conquer Cancer Foundation

Active, not recruiting

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
University of California, San Francisco

Completed

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence (PSMA BCR)

Prostate Cancer

United States
Mayo Clinic

Withdrawn

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Thomas Hope

Completed

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

Prostate Cancer

United States
University of California, San Francisco

Completed

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients (PSMA PreRP)

Prostate Cancer

United States
Thomas Hope

Completed

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
Mayo Clinic

Completed

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Terminated

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Jonsson Comprehensive Cancer Center

Terminated

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Mayo Clinic

Recruiting

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8

United States
Jonsson Comprehensive Cancer Center

Recruiting

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Prostate Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
University of Washington

Recruiting

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy (PSMA SRT)

Recurrent Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Completed

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than Fifty

United States
Jonsson Comprehensive Cancer Center

Completed

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer (MSG PSMA PET)

Prostate Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI); United States Department of Defense

Recruiting

68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer

Hepatocellular Carcinoma

United States
Jonsson Comprehensive Cancer Center
Society of Nuclear Medecine and Molecular Imaging

Recruiting

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Breast Carcinoma | Gastric Carcinoma | Head and Neck Carcinoma | Lung Carcinoma | Ovarian Carcinoma | Colon Carcinoma | Esophageal Carcinoma | Kidney Carcinoma | Pancreatic Carcinoma | Uterine Corpus Cancer | Solid Neoplasm

United States
Chang Gung Memorial Hospital

Completed

The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Metastatic Prostate Cancer

Taiwan
UNC Lineberger Comprehensive Cancer Center

Active, not recruiting

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Prostate Cancer

United States
Chang Gung Memorial Hospital

Recruiting

68Ga-PSMA PET/CT for Ra223 Assessment

Metastatic Prostate Cancer

Taiwan
UNC Lineberger Comprehensive Cancer Center

Withdrawn

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Prostate Cancer

United States
Jin-Sook Ryu

Active, not recruiting

Ga-68 PSMA-11 PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: Digital PET/CT Versus Analog PET/CT

Prostate Cancer

Korea, Republic of
Mayo Clinic

Completed

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

Hepatocellular Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Lobular Carcinoma | Metastatic Breast Lobular Carcinoma

United States
Chang Gung Memorial Hospital

Completed

Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer

Latent Cancer Prostate

Taiwan
University Health Network, Toronto

Not yet recruiting

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

Advanced Prostate Cancer

Canada
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
John O. Prior

Not yet recruiting

Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach (ThernSarc)

Soft Tissue Sarcoma
University of California, San Francisco
Radiological Society of North America

Completed

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
University of California, San Francisco

Terminated

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer

Thyroid Gland Carcinoma

United States
National Cancer Centre, Singapore

Active, not recruiting

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers

Salivary Gland Tumor | Rare Malignant Neoplasm

Singapore
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Not yet recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
Case Comprehensive Cancer Center

Completed

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

Breast Cancer | Lung Cancer | Prostate Cancer | Prostate-specific Membrane Antigen Positive Tumors

United States
Telix International Pty Ltd
Grand Pharmaceutical (China) Co., Ltd.

Recruiting

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Prostate Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate | BCR Prostate Carcinoma

China
Thomas Hope

Completed

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients (PSMA PET)

Prostate Cancer

United States
Norbert Avril, M.D.

Completed

Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

Prostate Cancer

United States
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed (PSMA-PROSTAPET)

Neoplasms | Urogenital Neoplasms | Disease Attributes | Prostate Cancer | Prostatic Neoplasm | Prostatic Disease

Italy
Anhui Provincial Hospital

Recruiting

Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Prostate Cancer | PET/CT

China
Five Eleven Pharma, Inc.
Indiana University

Active, not recruiting

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Prostate Cancer | Prostate Cancer Recurrent

United States
Mayo Clinic

Not yet recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
The Methodist Hospital Research Institute

Completed

68 Ga-PSMA for High Risk Prostate Cancer

Prostate Cancer | High Risk

United States
Jules Bordet Institute

Recruiting

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. (PRISMA)

TNBC - Triple-Negative Breast Cancer

Belgium
Gulhane Training and Research Hospital

Recruiting

Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging

Prostate Cancer | Prostate Cancer Stage

Turkey
Timothy Hoffman
University of Missouri-Columbia; Harry S. Truman Memorial Veterans' Hospital; Telix Pharmaceuticals, Ltd

Terminated

Ga-68-PSMA-11 in Men With Prostate Cancer (Ga68-PSMA-11)

Prostate Cancer | Prostate Adenocarcinoma

United States

Search clinical trials for: Ga-68 labeled PSMA-11 PET

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations